Market Place
Sourcing Support
Roche Purchases Shares In Tender Offer For 89Bio
30 Oct 2025 //
GLOBENEWSWIRE
Roche Starts Tender Offer For 89bio At $14.50/share in Cash
01 Oct 2025 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
05 Sep 2025 //
GLOBENEWSWIRE
89bio to Participate in Upcoming Investor Conferences
28 Aug 2025 //
GLOBENEWSWIRE
89bio Grants Inducements Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2025 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
09 Jul 2025 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
06 Jun 2025 //
GLOBENEWSWIRE
89bio to Join Goldman Sachs 46th Annual Healthcare Conference
04 Jun 2025 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
09 May 2025 //
GLOBENEWSWIRE
89bio to Participate in Upcoming Investor Conferences
06 May 2025 //
GLOBENEWSWIRE
89bio Reports Q1 2025 Financial Results and Updates
01 May 2025 //
GLOBENEWSWIRE
89bio to Participate in Leerink Partners Global Conference
03 Mar 2025 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
06 Feb 2025 //
GLOBENEWSWIRE
89bio Closes Public Offering, Underwriters` Option Fully Exercised
03 Feb 2025 //
GLOBENEWSWIRE
89bio $250M Public Offering Of Common Stock & Pre-Funded Warrants
28 Jan 2025 //
BIOSPACE
89bio Provides Business Update and Outlook for 2025
13 Jan 2025 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
19 Dec 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
29 Nov 2024 //
GLOBENEWSWIRE
89bio to Participate in 7th Annual Evercore HealthCONx Conference
26 Nov 2024 //
GLOBENEWSWIRE
89bio Announces Proposed Public Offering of Common Stock
12 Nov 2024 //
GLOBENEWSWIRE
89bio Announces Upsized Pricing of $125.0 Million Public Offering
12 Nov 2024 //
GLOBENEWSWIRE
89bio Reports Q3 2024 Financial Results & Corporate Updates
07 Nov 2024 //
GLOBENEWSWIRE
89bio to Participate in UBS Global Healthcare Conference
05 Nov 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Oct 2024 //
GLOBENEWSWIRE
89bio To Participate In HC Wainwright 8th Annual MASH Conference
30 Sep 2024 //
GLOBENEWSWIRE
89bio Appoints Teresa Perney As Chief Regulatory Officer
16 Sep 2024 //
GLOBENEWSWIRE
89bio to Participate in Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Aug 2024 //
GLOBENEWSWIRE
89bio Appoints Francis Sarena as Chief Operating Officer
07 Aug 2024 //
GLOBENEWSWIRE
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
05 Aug 2024 //
GLOBENEWSWIRE
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
05 Aug 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Jul 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Jun 2024 //
GLOBENEWSWIRE
89bio To Present ENLIVEN MASH 48-Week Data At EASL
22 May 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 May 2024 //
GLOBENEWSWIRE
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
09 May 2024 //
GLOBENEWSWIRE
89bio to Participate in the BofA Securities 2024 Health Care Conference
08 May 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08 Mar 2024 //
GLOBENEWSWIRE
89bio to Participate in the Leerink Partners Global Biopharma Conference
05 Mar 2024 //
GLOBENEWSWIRE
89bio Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
89bio to Participate in the Oppenheimer 34th Annual Life Sciences Conference
06 Feb 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Feb 2024 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Dec 2023 //
GLOBENEWSWIRE
89bio Announces Closing of its Upsized Public Offering
12 Dec 2023 //
GLOBENEWSWIRE
89bio Announces Upsized Pricing of $150.0M Public Offering of Common Stock
07 Dec 2023 //
GLOBENEWSWIRE
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock
06 Dec 2023 //
GLOBENEWSWIRE
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
21 Nov 2023 //
GLOBENEWSWIRE
89bio Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
89bio to Participate in H.C. Wainwright 7áµ—Ê° Annual NASH Investor Conference
17 Oct 2023 //
GLOBENEWSWIRE
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2023 //
GLOBENEWSWIRE
89bio to Participate in the 2023 Cantor Global Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
89bio to Participate in the H.C. Wainwright 25th Annual Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
89bio Reports Second Quarter 2023 Financial Results & Provides Corporate Update
09 Aug 2023 //
GLOBENEWSWIRE
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 Jul 2023 //
GLOBENEWSWIRE
Ex-Novartis drug clears NASH test, fueling pursuit of Akero
21 Jun 2023 //
FIERCE BIOTECH
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2023 //
GLOBENEWSWIRE
89bio Announces Late-Breaker Presentation of Data from the Phase 2 ENLIVEN Study
07 Jun 2023 //
GLOBENEWSWIRE
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
04 May 2023 //
GLOBENEWSWIRE
89bio to Participate in Upcoming Investor Conferences
02 May 2023 //
GLOBENEWSWIRE
